Cerep Inks Kinase-Profiling Agreement with Lilly | GenomeWeb

NEW YORK (GenomeWeb News) - Cerep today said that it has signed an agreement with Eli Lilly & Co. covering the use of its kinase assay platform to study undisclosed drug targets.

The agreement is an extension of an existing deal between the two companies for access to Cerep's GPCR screening portfolio.

Cerep's kinase profiling service is based on PerkinElmer's Lance Ultra kinase assay technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.